Personalized cancer vaccines

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

217 papers

Showing 1-12 of total 217 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026CrossrefDirectly related0 citations

Evaluation of Computational Neoantigen Prioritization Strategies for Personalized Cancer Vaccines

Vladimir Zyrin; Evgeniy Mozheiko; Ivan Valiev; Alexey Lazarev; Tigran Gevorkyan; Matvey Murashko; Konstantin Okonechnikov

Sep 28, 2026Vaccines

2026CrossrefSupporting evidence0 citations

First mRNA‑based flu vaccine wins US approval, Moderna’s Ebola candidate reaches the clinic, and early‑phase cancer vaccine trials broaden across personalized and off‑the‑shelf platforms

Ashling Cannon

Sep 10, 2026Vaccine Insights

2026arXivDirectly related

Optimizing RNA yield using deep neural networks coupled to massively parallel screening

Dinghai Zheng; Justin Hong; Jun Wang; Adrien Villain; Mickaël Costallat; Fernando Ulloa Montoya; Vikram Agarwal

Aug 24, 2026

2026CrossrefDirectly related0 citations

Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction

Petar Brlek; Jan Kolić; Luka Bulić; Vedrana Škaro; Dragan Primorac

Jul 29, 2026Frontiers in Genetics

2026CrossrefDirectly related0 citations

Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines

Almohanad A. Alkayyal

Feb 26, 2026Pharmaceuticals

2026PubMedSupporting evidence

Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.

Crodel CC; Gork L; Göpel W; Linke P; Sinn K; Miethke J; Hochhaus A; Hilgendorf I

Jan 1, 2026Journal of cancer research and clinical oncology

2026PubMedSupporting evidence

Engineering smart polymeric lipid nanoparticles for breast cancer: The convergence of AI and medical personalization to enhance efficacy and safety.

Sayed U; Azamova D; Abdulqader AF; Kadhim AA; Jamuna KV; Singhal D; Tailor NK; Polatova D

Jan 1, 2026International journal of pharmaceutics

2026PubMedSupporting evidence

NR2C2 suppresses breast cancer progression and promotes T-Cell infiltration in the tumor microenvironment.

Li X; Yu X; Huang K; Luo S; Li J; Song C; Zhang J

Jan 1, 2026Journal of molecular histology

2026PubMedSupporting evidence

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies.

Dhillon S; Rathod H; Dhillon S

Jan 1, 2026Cureus

2026PubMedDirectly related

Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.

Wu YF; Hu JC; Hu YF; Li WJ; Rong L; Li RH; Yao Y; Hu L; Wang XL; Zhang BZ; Lu Y; Chow SF; Su C; Yau T; Chung CY; Huang JD

Jan 1, 2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2026PubMedDirectly related

Biomimetic nano-in-gel vaccine platform with spatiotemporal co-delivery capacity for DC maturation against immunosuppressive tumors.

Wu J; Bu X; Liu Z; Zhou Y; Zhang L; Wang Z; Cheng W; Yu Y; Xu H; Gu Q

Jan 1, 2026International journal of pharmaceutics: X

2026PubMedSupporting evidence

Targeting the Siglec/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms.

Lee D; ElNemer W; Selim O; Patel P; Freeman S; Slika H; Ruchika F; Brem H; Jackson C; Tyler BM

Jan 1, 2026Neuro-oncology advances